ProCE Banner Activity


Immunotherapy and Beyond in Metastatic NSCLC: Where Are We Now and What’s Next?


On-demand webcast of expert faculty presentation and case discussions on the role of immunotherapy, in combination with other modalities, for the treatment of patients with metastatic non-small-cell lung cancer.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: December 12, 2023

Expiration: December 11, 2024



Christine M. Bestvina

Christine M. Bestvina, MD

Assistant Professor
Section of Hematology/Oncology
Division of Medicine
University of Chicago Medicine
Chicago, Illinois

Elaine Shum

Elaine Shum, MD

Assistant Professor
NYU Grossman School of Medicine
NYU Perlmutter Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from AstraZeneca.


Target Audience

This program is intended for medical oncologists and other healthcare professionals who care for patients with lung cancer.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment with immunotherapy for patients with metastatic NSCLC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select optimal immunotherapy-based regimens for patients with metastatic NSCLC 

  • Assess how emerging novel treatments and immunotherapy agents for metastatic NSCLC might be integrated into current treatment paradigms

  • Develop multidisciplinary team strategies to effectively mitigate and manage adverse events associated with immunotherapies in patients with metastatic NSCLC while maintaining the most effective treatment regimens

  • Foster health equity via identification of diverse patient populations suitable for enrollment in ongoing clinical trials and treatment strategies employing immunotherapy for patients with metastatic NSCLC


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Christine M. Bestvina, MD

Assistant Professor
Section of Hematology/Oncology
Division of Medicine
University of Chicago Medicine
Chicago, Illinois

Christine M. Bestvina, MD: researcher: AstraZeneca, Bristol Myers Squibb; consultant/advisor/speaker: AstraZeneca, Bristol Myers Squibb, CVS, Daiichi Sankyo, EMD Serono, Gilead, Mirati, Novocure, Regeneron, Sanofi, Takeda, Tempus. 

Elaine Shum, MD

Assistant Professor
NYU Grossman School of Medicine
NYU Perlmutter Cancer Center
New York, New York

Elaine Shum, MD: consultant/advisor/speaker: AstraZeneca, Blueprint Medicines, Boehringer Ingelheim, Genentech, Gilead, Regeneron; researcher (paid to institution): Delfi Diagnostics.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 12, 2023, through December 11, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.